Next Article in Journal
Early Postoperative Death in Patients Undergoing Emergency High-Risk Surgery: Towards a Better Understanding of Patients for Whom Surgery May not Be Beneficial
Next Article in Special Issue
New Treatment Options for Hyperkalemia in Patients with Chronic Kidney Disease
Previous Article in Journal
Compliance of Atrial Fibrillation Treatment with the Atrial Fibrillation Better Care (ABC) Pathway Improves the Clinical Outcomes in the Middle East Population: A Report from the Gulf Survey of Atrial Fibrillation Events (SAFE) Registry
Previous Article in Special Issue
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
Review

Calciprotein Particles and Serum Calcification Propensity: Hallmarks of Vascular Calcifications in Patients with Chronic Kidney Disease

1
Department of Molecular Sciences, University of Medicine and Pharmacy “Iuliu Hațieganu”, 400012 Cluj-Napoca, Romania
2
Department of Nephrology & Epidemiology and Biostatistics, Amsterdam UMC, location VUmc, 1117 HV Amsterdam, Netherlands
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(5), 1287; https://doi.org/10.3390/jcm9051287
Received: 1 April 2020 / Revised: 27 April 2020 / Accepted: 29 April 2020 / Published: 29 April 2020
(This article belongs to the Special Issue A Changing Perspective for Treatment of Chronic Kidney Disease)
Cardiovascular complications are one of the leading causes of mortality worldwide and are strongly associated with atherosclerosis and vascular calcification (VC). Patients with chronic kidney disease (CKD) have a higher prevalence of VC as renal function declines, which will result in increased mortality. Serum calciprotein particles (CPPs) are colloidal nanoparticles that have a prominent role in the initiation and progression of VC. The T50 test is a novel test that measures the conversion of primary to secondary calciprotein particles indicating the tendency of serum to calcify. Therefore, we accomplished a comprehensive review as the first integrated approach to clarify fundamental aspects that influence serum CPP levels and T50, and to explore the effects of CPP and calcification propensity on various chronic disease outcomes. In addition, new topics were raised regarding possible clinical uses of T50 in the assessment of VC, particularly in patients with CKD, including possible opportunities in VC management. The relationships between serum calcification propensity and cardiovascular and all-cause mortality were also addressed. The review is the outcome of a comprehensive search on available literature and could open new directions to control VC. View Full-Text
Keywords: calciprotein particles; calcification propensity; chronic kidney disease; vascular calcification calciprotein particles; calcification propensity; chronic kidney disease; vascular calcification
Show Figures

Figure 1

MDPI and ACS Style

Silaghi, C.N.; Ilyés, T.; Van Ballegooijen, A.J.; Crăciun, A.M. Calciprotein Particles and Serum Calcification Propensity: Hallmarks of Vascular Calcifications in Patients with Chronic Kidney Disease. J. Clin. Med. 2020, 9, 1287. https://doi.org/10.3390/jcm9051287

AMA Style

Silaghi CN, Ilyés T, Van Ballegooijen AJ, Crăciun AM. Calciprotein Particles and Serum Calcification Propensity: Hallmarks of Vascular Calcifications in Patients with Chronic Kidney Disease. Journal of Clinical Medicine. 2020; 9(5):1287. https://doi.org/10.3390/jcm9051287

Chicago/Turabian Style

Silaghi, Ciprian N., Tamás Ilyés, Adriana J. Van Ballegooijen, and Alexandra M. Crăciun. 2020. "Calciprotein Particles and Serum Calcification Propensity: Hallmarks of Vascular Calcifications in Patients with Chronic Kidney Disease" Journal of Clinical Medicine 9, no. 5: 1287. https://doi.org/10.3390/jcm9051287

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop